Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus AFEDITAB CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus AFEDITAB CR.
ADALAT CC vs AFEDITAB CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker